Progyny Balanced Scorecard
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Make Smarter Expansion Decisions with the Full Report
This Progyny Balanced Scorecard Analysis gives you a clear, company-specific view of strategic priorities across financial, customer, internal process, and learning and growth areas. The page already shows a real preview of the actual report content, so you can review the format and substance before buying. Purchase the full version to get the complete ready-to-use analysis.
Benefits
Cost Clarity
Cost Clarity is a real benefit in Progyny's Balanced Scorecard because the model ties better fertility care to lower avoidable spend. IVF can run about $15,000 to $25,000 per cycle before drugs, so even small gains from provider steering and pharmacy control can move employer totals fast.
That makes it easier to test whether higher care quality is also cutting repeat cycles, drug waste, and claims leakage. In practice, the scorecard can show if better outcomes are lowering total cost per member, not just shifting spend around.
Renewal Signal
Renewal signal is a key scorecard metric for Progyny because employer retention shows the benefit is worth keeping after the first 12 months. If clients renew and covered lives expand, that points to stronger value capture and lower churn in a recurring benefits model. In 2025, watching renewal rates, client count, and covered lives together gives the cleanest read on whether the fertility benefit is sticking.
Pharmacy Control
In fiscal 2025, Progyny's integrated pharmacy benefit gives it a direct way to manage one of fertility care's biggest cost drivers. By watching fill rates, specialty-drug spend, and off-network leakage, it can test whether members are using the intended channel and whether waste is falling. A tighter pharmacy loop should support lower avoidable spend and cleaner unit economics.
Provider Steering
Provider steering measures whether Progyny members are directed to higher-quality fertility clinics, which can improve outcomes and reduce waste in care paths. In fertility care, better site selection can mean fewer failed cycles, tighter coordination, and less time lost between consult, treatment, and follow-up. For employers, that makes the vendor story clearer because they can compare not just access and cost, but whether the benefit is steering care toward stronger clinical results.
Family-Building Breadth
Progyny's family-building breadth covers 3 paths: IVF, egg freezing, and adoption support. In the scorecard, that helps test whether one platform is widening employer relevance, since buyers often want one vendor, one contract, and one reporting view across multiple member needs.
This matters in 2025 because broader coverage can lift retention and cross-sell without adding admin load, which is the kind of signal employers pay for.
Progyny's Edge: Lower Fertility Costs, Stronger Employer Value
Benefits are strongest when Progyny proves better fertility care lowers total employer spend, not just improves access. In 2025, IVF still costs about $15,000-$25,000 per cycle before drugs, so steering, pharmacy control, and fewer failed cycles can move results fast. Broader coverage across IVF, egg freezing, and adoption also raises retention and cross-sell.
| Benefit | 2025 signal |
|---|---|
| Cost clarity | $15k-$25k per IVF cycle |
| Scope | 3 family-building paths |
What is included in the product
Detailed Word Document
Editable Excel File
Drawbacks
Attribution Risk
Attribution risk is high because fertility outcomes depend on age, diagnosis, and protocol, not just Progyny's model. In IVF, live-birth odds can fall from about 40% under age 35 to under 10% at ages 42-43, so better results do not prove service impact. That makes it hard to assign credit when scores move up or down, especially across mixed employer groups and treatment paths.
Time Lag
Many fertility journeys take 6 to 12 months, and some run longer, so a quarterly balanced scorecard can miss real progress. That lag can make Progyny look flat in one period and then strong in the next, even when member outcomes are improving. It can also trigger bad moves from one noisy quarter, like cutting support too soon or overrewarding short-term spikes. The metric works best when paired with rolling 12-month views, since the underlying cycle often outlasts a single quarter.
External Price Pressure
External price pressure can make Progyny's Balanced Scorecard look worse even when service quality is steady. Fertility drug and provider fee moves sit outside management control, so a 5% to 10% cost spike can lift client spend fast and squeeze margin. In 2025, that means cost metrics can weaken from input inflation, not from execution failure.
Third-Party Dependence
Progyny's model depends on employer HR teams, fertility clinics, and pharmacy partners, so service quality can slip outside its control. If an employer delays enrollment or a clinic has scheduling gaps, member experience and scorecard metrics can weaken even when Progyny's navigation is strong. That risk matters because the company's scale makes each partner miss visible across many covered lives at once.
Data Integration
Data integration is a weak spot because a balanced scorecard only works when claims, utilization, and outcomes are captured the same way across clients and care settings. Progyny must normalize data from employers, health plans, and provider groups, and that cleanup can take weeks, which delays scorecard updates. If reporting is messy or late, small shifts in fertility treatment quality or member outcomes can get blurred instead of flagged fast.
Why Progyny's Scorecard Can Mislead Investors
Progyny's scorecard can blur causality because IVF live-birth odds fall from about 40% under age 35 to under 10% at ages 42-43, so outcomes reflect patient mix as much as execution.
Timing is another flaw: many fertility journeys last 6-12 months, so a quarterly view can miss real progress and overreact to one noisy period.
In 2025, 5%-10% cost swings in drugs or provider fees can lift client spend fast, while partner delays and messy data can hide service gaps.
Get Your Copy
Progyny Reference Sources
This Progyny Balanced Scorecard analysis preview is the same document you'll receive after purchase, with no changes or hidden sections. It offers a real look at the full report's strategic, financial, customer, internal process, and learning perspectives. Once purchased, the complete Balanced Scorecard analysis is unlocked in full detail.
Frequently Asked Questions
It measures whether Progyny is delivering better fertility outcomes at an acceptable cost. The most useful indicators are 4 perspectives: financial, customer, internal process, and learning and growth, plus employer retention, member experience, and pharmacy spend. In this business, clinical outcomes and total benefit cost matter more than raw member counts.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.